By Chris WackPasithea Therapeutics said it has received Investigational New Drug Application clearance to proceed by the Federal Drug Administration to evaluate PAS-004 in cancer patients. Pasithea stock was halted at $7.40 in premarket trading on the news. PAS-004 is a macrocyclic MEK inhibitor for patients with advanced solid tumors with a documented mutation or patients who have failed BRAF/MEK inhibition. Pasithea expects to dose the first patient in the first quarter of 2024. Write to Chris Wack at chris.wack@wsj.com(END) Dow Jones Newswires01-02-24 0902ET

Source: Wall Street Journal January 02, 2024 14:04 UTC